Medistem's Acquisition Hints at Big Potential.

The article reports on the acquisition of a San Diego, California-based stem cell firm, Medistem Inc., by a Germantown, Maryland-based synthetic biology company, Intrexon Corp. for about $26 million. The ability and potency of Medistem's endometrial regenerative cells will be expanded by the genetic engineering capabilities of Intrexon, according to Alan Lewis of Medistem. Medistem's stockholders will receive 27 cents in exchange for each share of Medistem common stock in cash.